NARA Discovery
Article Details
← Back to Search Results
Journal Article

Putative involvement of sirtuin modulators in LPS-induced sickness behaviour in mice

Manas Kinra; Niraja Ranadive; Jayesh Mudgal; Yuqing Zhang; Anusha Govindula; Shailendra Anoopkumar-Dukie; Andrew K. Davey; Gary D. Grant; Madhavan Nampoothiri; Devinder Arora
Metabolic Brain Disease · Vol. 37, Issue 6 · pp. 1969-1976 · 2022

Abstract

NAD + —dependent histone deacetylases (sirtuins 1–7) have been shown to be involved in various pathophysiological conditions including their involvement in cardiovascular, cancerous, neurodegenerative, immune dysregulation and inflammatory conditions. This study investigates the inflammomodulatory potential of resveratrol (RES), a sirtuin activator and sirtinol (SIR), a sirtuin inhibitor in lipopolysaccharide (LPS)-induced model of sickness behaviour in mice. Male Swiss albino mice were divided into five groups (n = 6) consisting of saline (SAL), LPS, RES, SIR, and fluoxetine (FLU) respectively, each group except LPS was prepared by intraperitoneally (i.p.) administration of SAL (10 mL/kg), RES (50 mg/kg), SIR (2 mg/kg) and FLU (10 mg/kg). Thirty minutes after the treatments, all the groups, except SAL were administered LPS (2 mg/kg, i.p.). The behavioural assays including, open field test, forced swim test, and tail suspension tests were conducted 1 h after LPS challenge. LPS administration significantly reduced the locomotor activity along with inducing a state of high immobility and that was prevented by pretreatment with RES and SIR. Further, various proinflammatory cytokines (TNF-α, IL-6, and IL-1β), and oxidative stress markers (MDA and GSH) were found to be significantly elevated in the brain homogenates after LPS treatment. SIR pretreatment abrogated the LPS-induced neuroinflammatory and oxidative stress changes, whereas RES was only effective in reducing the oxidative stress and TNF-α levels. The results of this study speculate that the role of SIRT modulators in neuroinflammatory conditions could vary with their dose, regimen and chemical properties. Further studies with detailed molecular and pharmacokinetic profiling will be needed to explore their therapeutic potentials.

Bibliographic Information

JournalMetabolic Brain Disease
PublisherSpringer
Publication Date2022-08-01
Publication Year2022
Volume37
Issue6
Pages1969-1976
Document TypeJournal Article
eISSN1573-7365
DOI10.1007/s11011-022-00992-9

Access Information

NARA Access Coverage1986-01-01~Current
Journal Homepagehttps://www.springer.com/journal/11011
Publisher PageOpen Publisher Page
Full-text access depends on NARA's subscribed coverage and institutional access.